Loading...
Immunotherapies for Infectious Diseases Congress 2018

December 10 - 11 LYON - Matmut Stadium

News Twitter

Program

schedule & speakers

Your company develops immunotherapies for infectious diseases and you want to present your scientific work at the I4ID 2018 congress? Check-out our sponsors & partners page to discover our sponsored presentation opportunities.

Day 1

Monday 10 December 2018

8h30

Registration & welcome coffee

9h00

Welcome address

9h15

Keynote Lecture

Prof. Stefan H. Kaufmann

Prof. Stefan H. Kaufmann
Director
Max Planck Institute for Infection Biology, Germany
Professor
Charité University Clinics, Germany
Tuberculosis control: the need for better diagnosis, therapy and prevention

10h00

Session I – Targeting the Immune system to fight Bacterial Infections

Caroline Demangel

Caroline Demangel
Head of Immunobiology of Infection Unit
Institut Pasteur and INSERM U1221, France
Lost in translocation: a mechanism of immune suppression revealed by Mycobacterium ulcerans

10h30

Coffee break & Poster Session at Exhibition Hall | Partnering (B2B meetings)

11h00

Session I – Targeting the Immune system to fight Bacterial Infections

Markus Maeurer

Markus Maeurer
Head of the Champalimaud Immunotherapy Programme
Fundação Champalimaud
The cellular therapy of TB infection: MSCs - and ‘other’ cells

Wayne Dankner

Wayne Dankner
Chief Medical Officer
Atox Bio, Israel
Reltecimod: Novel Immunomodulator as Adjunctive Treatment to Improve Outcomes in Necrotizing Soft Tissue Infections and Sepsis-Associated Acute Kidney Injury

12h00

Lunch break

13h00

Poster Session – Poster presentations at Exhibition Hall

14h00

Session II – Targeting the Immune System to fight Sepsis

Dr. Richard Hotchkiss

Dr. Richard Hotchkiss
Professor of Anesthesiology, Medicine, and Surgery
Washington University School of Medicine, USA
Physician
Surgical Intensive Care Unit at Barnes Jewish Hospital in St Louis, USA
Immunotherapy of Sepsis – a new approach to a lethal disease

Prof. Guillaume Monneret

Prof. Guillaume Monneret
Head of Clinical Cellular Immunology Laboratory
Lyon University Hospitals, France
Head of EA 7426 - research unit on Pathophysiology of injury-induced immunosuppression
Lyon University, France
Monitoring immune alterations: toward personalized immunotherapy in sepsis

Desiree Perlee

Desiree Perlee
PhD student
Center of Experimental & Molecular Medicine, University of Amsterdam, Netherlands
Stem cells as a possible treatment for sepsis

Dr. Fabienne Venet

Dr. Fabienne Venet
Associated Professor, Physician
Lyon University Hospitals
EA 7426 - research unit on Pathophysiology of injury-induced immunosuppression
Joint Research Unit bioMérieux-Hospices Civils de Lyon-Université Claude Bernard Lyon 1, France
The REALISM (REAnimation Low Immune Status Markers) study

16h00

Coffee break & Poster Session at Exhibition Hall | Partnering (B2B meetings)

16h30

Pitch Session – Innovation on HDT approaches to treat Infectious Diseases

Jean-Claude Sirard
Project Leader
Institut Pasteur de Lille / Inserm, France
Therapeutic synergy between antibiotics and inhaled flagellin against pneumonia

Ana Esteve-Sole
Post-doctoral Researcher
Hospital Sant Joan de Déu. University of Barcelona, Spain
Altered IL-12/IFN-gamma pathway in extrapulmonary tuberculosis and visceral leishmaniasis in pediatric patients and related controls

Ignacio Santecchia
PhD Student
Institut Pasteur, France
title not available

Sébastien Tabruyn
CSO
TransCure BioServices, France
How humanized mice models helps to evaluate immunotherapy for infectious Diseases?

Philippe Personne
CEO
Signia Therapeutics, France
Repurposing of marketed drugs as novel host targeting antivirals from clinical gene expression infection signatures

Els Saesen
Business Developer
Agro-Bio, France
Emilie Escoffier
Project coordinator exploratory Science & translational medicine
Novimmune, Switzerland
Generation of anti-drug antibodies reagents for the development of immunogenicity assays for a novel bispecific drug antibody format

Grégory Destras
Trainee
Hospices Civils de Lyon- Infectious Agents Institute, France
Adoptive immunotherapy as a new therapeutic perspective for patients who underwent allogenic stem cells transplantation: case report of the first implementation of adenovirus-specific T-cells transfer in Lyon

Emmanuel Chereul
General Manager
VOXCAN
V O X C A N a unique CRO to perform your efficacy and biodistribution studies on level 2 and 3 infectious disease models using medical imaging

18h30

End of Day One

20h00

Cocktail Reception and Networking

Day 2

Tuesday 11 December 2018

8h30

Welcome coffee

8h45

Keynote Lecture

Eric Vivier

Eric Vivier
Professor of Immunology
Aix-Marseille University and Public Hospital of Marseille, France
CSO
Innate Pharma, France
Innate lymphoid cells: from discovery to cancer treatment

9h30

Session III – Targeting the Immune System to fight Viral Infections

Prof. Mala Maini

Prof. Mala Maini
Professor of Viral Immunology and Honorary Consultant
Division of Infection and Immunity at UCL, UK
Manipulating defective T cell immunity for HBV functional cure

Uzma Hasan

Uzma Hasan
Principal Investigator
CIRI – U1111 Inserm, France
Innate immune deregulation in infection cancers: lessons to be learned

10h30

Coffee break & Poster Session at Exhibition Hall | Partnering (B2B meetings)

11h00

Session III – Targeting the Immune System to fight Viral Infections

Dr. Carolina Boni

Dr. Carolina Boni
Researcher
University Hospital of Parma, Italy
Targeting innate immunity receptors and HBV-specific T cells to cure chronic HBV infection

David Durantel

David Durantel
Senior Researcher in Molecular Virology
INSERM, France
Innate immune agonists in immune-therapies against HBV/HDV infections

12h00

Lunch break

13h00

Poster Session – Poster presentations at Exhibition Hall

14h30

Session IV – Bringing into clinic Host-Directed Therapies: safety and efficiency

Pierre-François Laterre

Pierre-François Laterre
Head of the ICU
St. Luc University Hospital, UCL, Belgium
Companion diagnostic in Sepsis

Mark Miller

Mark Miller
Executive Vice President, Chief Medical Officer
bioMérieux, France
Companion, supportive and facilitating diagnostics for immunotherapy: why are we failing compared to oncology?

15h30

Coffee Break & Poster Session at Exhibition Hall | Partnering (B2B meetings)

16h00

Session V – Developing Next-Generation of host-directed therapies

Eric Meldrum

Eric Meldrum
Chief Scientific Officer
Enyo Pharma, France
A novel approach to identify host targeted therapies for infectious & non-infectious disease

Nicolas Manel

Nicolas Manel
Team Leader
Institut Curie, France
Research Director
INSERM, France
Unraveling the innate immune sensors of viruses

Dr. Rafael Mañez

Dr. Rafael Mañez
Director of Critical Care Medicine
Bellvitge University Hospital, Spain
Head of the research group Innate Immunity and Pathology of the Critical Patient
Bellvitge Biomedical Research Institute (IDIBELL), Spain
Hospitalet de Llobregat Barcelona, Spain
Founder
RemAb Therapeutics, Spain
Removal of non-killing antibodies elicits protective immunity against infections

17h30

Announcement of the Best Pitch & Best Poster

17h45

Closing remarks

18h00

End of Congress